{
  "parsed": [
    {
      "model": "claude",
      "raw": "\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-questions:**\n1. **Tissue pharmacokinetics:** What are the actual intracellular [Li\u207a] in brain neurons vs. renal collecting duct cells at low-dose (~0.2\u20130.4 mM plasma) vs. therapeutic-dose (~0.8\u20131.2 mM plasma)?\n2. **Target affinity hierarchy:** What are the EC50/Ki values for neuroprotective targets (GSK-3\u03b2 indirect pathway, BDNF upregulation) vs. nephrotoxic targets (IMPase, AQP2 pathway disruption)?\n3. **Accumulation asymmetry:** Why does kidney concentrate Li\u207a while brain equilibrates near plasma levels?\n4. **Cooperativity/threshold effects:** Is nephrotoxicity graded or threshold-dependent, and does this explain the narrow therapeutic index?\n\n**Key relationships:** Tissue accumulation ratio \u00d7 plasma [Li\u207a] = intracellular [Li\u207a] at target. Neuroprotection requires brain [Li\u207a] > GSK-3\u03b2_indirect EC50. Nephrotoxicity requires renal [Li\u207a] > IMPase Ki (~0.8 mM) sustained chronically.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM 1:** Differential tissue accumulation is the primary mechanistic driver \u2014 renal principal cells concentrate Li\u207a 3\u201310\u00d7 plasma via ENaC entry and poor basolateral efflux, while brain parenchyma equilibrates at 0.5\u20131.2\u00d7 plasma.\nTYPE: 1\nCONFIDENCE: 0.88\nMECHANISM: ENaC permeates Li\u207a \u2265 Na\u207a, but Na\u207a/K\u207a-ATPase and Na\u207a/H\u207a exchangers extrude Li\u207a at <10% the rate of Na\u207a, creating a concentration trap unique to ENaC-expressing epithelia.\nFALSIFIABLE BY: Microdialysis or ICP-MS showing renal medullary [Li\u207a] < 2\u00d7 plasma at steady-state therapeutic dosing, or brain [Li\u207a] > 3\u00d7 plasma.\n\n**CLAIM 2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [Li\u207a] of 0.2\u20130.4 mM.\nTYPE: 1\nCONFIDENCE: 0.85\nMECHANISM: Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression.\nFALSIFIABLE BY: Demonstrating that Ser9A knock-in mice (phospho-dead GSK-3\u03b2) still show lithium neuroprotection at low doses, or that direct Ki (~2 mM) is required.\n\n**CLAIM 3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient.\nTYPE: 2\nCONFIDENCE: 0.70\nMECHANISM: At renal intracellular [Li\u207a] > 2 mM, convergent inositol depletion, COX-2 upregulation, and impaired vasopressin signaling cooperatively trigger interstitial fibrosis and nephrogenic diabetes insipidus.\nFALSIFIABLE BY: Showing linear dose-response for renal biomarkers (NGAL, KIM-1) across the full plasma range 0.2\u20131.5 mM, contradicting threshold behavior.\n\n**CLAIM 4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 while kidney [Li\u207a] reaches 5\u201315 mM.\nTYPE: 2\nCONFIDENCE: 0.75\nMECHANISM: The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma.\nFALSIFIABLE BY: Paired brain MRS lithium imaging and renal biopsy [Li\u207a] measurements showing <3-fold tissue concentration difference.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\n\n- **Precise renal accumulation ratios in humans** \u2014 most data from rat models; human collecting duct [Li\u207a] at steady state poorly characterized.\n- **Relative contribution",
      "claims": [
        {
          "statement": "1:** Differential tissue accumulation is the primary mechanistic driver \u2014 renal principal cells concentrate Li\u207a 3\u201310\u00d7 plasma via ENaC entry and poor basolateral efflux, while brain parenchyma equilibrates at 0.5\u20131.2\u00d7 plasma.",
          "type": 1,
          "confidence": 0.88,
          "mechanism": "ENaC permeates Li\u207a \u2265 Na\u207a, but Na\u207a/K\u207a-ATPase and Na\u207a/H\u207a exchangers extrude Li\u207a at <10% the rate of Na\u207a, creating a concentration trap unique to ENaC-expressing epithelia.",
          "falsifiable_by": "Microdialysis or ICP-MS showing renal medullary [Li\u207a] < 2\u00d7 plasma at steady-state therapeutic dosing, or brain [Li\u207a] > 3\u00d7 plasma."
        },
        {
          "statement": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [Li\u207a] of 0.2\u20130.4 mM.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression.",
          "falsifiable_by": "Demonstrating that Ser9A knock-in mice (phospho-dead GSK-3\u03b2) still show lithium neuroprotection at low doses, or that direct Ki (~2 mM) is required."
        },
        {
          "statement": "3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient.",
          "type": 2,
          "confidence": 0.7,
          "mechanism": "(effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient.",
          "falsifiable_by": "Showing linear dose-response for renal biomarkers (NGAL, KIM-1) across the full plasma range 0.2\u20131.5 mM, contradicting threshold behavior."
        },
        {
          "statement": "4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 while kidney [Li\u207a] reaches 5\u201315 mM.",
          "type": 2,
          "confidence": 0.75,
          "mechanism": "The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma.",
          "falsifiable_by": "Paired brain MRS lithium imaging and renal biopsy [Li\u207a] measurements showing <3-fold tissue concentration difference. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "---\n### **SECTION 1: DECOMPOSITION**\n**Sub-questions:**\n1. **Dose-dependent target engagement:** Why does low-dose lithium (0.1\u20130.5 mM plasma) inhibit GSK-3\u03b2 in the brain but not trigger nephrotoxicity, while therapeutic doses (0.6\u20131.2 mM) do?\n2. **Tissue-specific bioaccumulation:** How do brain vs. kidney cells differentially accumulate lithium, and how does this relate to their respective toxicity thresholds?\n3. **Molecular thresholds:** What are the intracellular [Li\u207a] thresholds for GSK-3\u03b2 inhibition (neuroprotection) vs. IMPase inhibition/ENaC disruption (nephrotoxicity)?\n4. **Cooperativity & nonlinearity:** Does nephrotoxicity exhibit Hill coefficients >1 due to cooperative damage pathways (e.g., inflammasome activation)?\n\n**Key variables:**\n- Plasma [Li\u207a] (input)\n- Intracellular [Li\u207a] (brain vs. kidney)\n- GSK-3\u03b2 IC\u2085\u2080 (0.2\u20132 mM) vs. IMPase Ki (~0.8 mM)\n- ENaC permeability (Li\u207a/Na\u207a ratio)\n- Na\u207a/K\u207a-ATPase efflux efficiency for Li\u207a\n- Hill coefficients for neuroprotection (n=1) vs. nephrotoxicity (n>1?)\n\n---\n\n### **SECTION 2: CLAIMS**\n\n**CLAIM 1:** *Low-dose lithium achieves neuroprotection via indirect GSK-3\u03b2 inhibition (Akt-mediated Ser9 phosphorylation) at intracellular [Li\u207a] ~0.2\u20130.5 mM, below the direct Mg\u00b2\u207a-competitive Ki (~2 mM).*\n**TYPE:** 1 (mechanistic, quantitative)\n**CONFIDENCE:** 0.90\n**MECHANISM:** Lithium disrupts PP1-Akt-GSK-3\u03b2 feedback loops, lowering the effective EC\u2085\u2080 for GSK-3\u03b2 inhibition to ~0.3 mM intracellularly, while brain [Li\u207a] equilibrates at ~0.8\u20131.5\u00d7 plasma levels.\n**FALSIFIABLE BY:** If brain [Li\u207a] at low doses exceeds 0.5 mM *without* GSK-3\u03b2 inhibition (e.g., in Akt-knockout mice) or if direct GSK-3\u03b2 inhibition requires >1 mM intracellular [Li\u207a].\n\n---\n\n**CLAIM 2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) and disrupting AQP2 trafficking.*\n**TYPE:** 1 (mechanistic, quantitative)\n**CONFIDENCE:** 0.92\n**MECHANISM:** ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress.\n**FALSIFIABLE BY:** If ENaC-knockout mice show no renal [Li\u207a] accumulation or nephrotoxicity at therapeutic doses, or if intracellular [Li\u207a] in principal cells remains <1 mM at 0.8 mM plasma.\n\n---\n\n**CLAIM 3:** *Nephrotoxicity exhibits a Hill coefficient >1 (n=1.5\u20133) due to cooperative damage pathways (e.g., NLRP3 inflammasome activation) triggered by lysosomal Li\u207a overload.*\n**TYPE:** 2 (hypothesis, testable)\n**CONFIDENCE:** 0.75\n**MECHANISM:** Intracellular [Li\u207a] >5 mM disrupts lysosomal pH, releasing cathepsins that activate NLRP3, creating a nonlinear toxicity threshold.\n**FALSIFIABLE BY:** If NLRP3-knockout mice show linear nephrotoxicity (n=1) or if lysosomal pH remains stable at [Li\u207a] <5 mM.\n\n---\n\n**CLAIM 4:** *The therapeutic index (TI) of lithium is artifactually low (~2\u20133) because brain [Li\u207a] remains below nephrotoxic thresholds (1\u20132 mM) at therapeutic doses, while kidney [Li\u207a] reaches 4\u201316 mM.*\n**TYPE:** 1 (quantitative)\n**CONFIDENCE:** 0.85\n**MECHANISM:** Brain [Li\u207a] saturates at ~1.5\u00d7 plasma (0.9\u20131.8 mM at 0.6\u20131.2 mM plasma), below IMPase Ki, while kidney [Li\u207a] accumulates to 5\u201320\u00d7 plasma, exceeding toxicity thresholds.\n**FALSIFIABLE BY:** If brain [Li\u207a] at therapeutic doses exceeds 2 mM or if kidney [Li\u207a] remains <2 mM at 0.8 mM plasma.\n\n---\n\n**CLAIM 5:** *ENaC\u2019s Li\u207a permeability is the primary determinant of nephrotoxicity, not systemic [Li\u207a].*\n**TYPE:** 2 (hypothesis)\n**CONFIDENCE:** 0.80\n**",
      "claims": [
        {
          "statement": "1:** *Low-dose lithium achieves neuroprotection via indirect GSK-3\u03b2 inhibition (Akt-mediated Ser9 phosphorylation) at intracellular [Li\u207a] ~0.2\u20130.5 mM, below the direct Mg\u00b2\u207a-competitive Ki (~2 mM).",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "Lithium disrupts PP1-Akt-GSK-3\u03b2 feedback loops, lowering the effective EC\u2085\u2080 for GSK-3\u03b2 inhibition to ~0.3 mM intracellularly, while brain [Li\u207a] equilibrates at ~0.8\u20131.5\u00d7 plasma levels.",
          "falsifiable_by": "If brain [Li\u207a] at low doses exceeds 0.5 mM *without* GSK-3\u03b2 inhibition (e.g., in Akt-knockout mice) or if direct GSK-3\u03b2 inhibition requires >1 mM intracellular [Li\u207a]. ---"
        },
        {
          "statement": "2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) and disrupting AQP2 trafficking.",
          "type": 1,
          "confidence": 0.92,
          "mechanism": "ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress.",
          "falsifiable_by": "If ENaC-knockout mice show no renal [Li\u207a] accumulation or nephrotoxicity at therapeutic doses, or if intracellular [Li\u207a] in principal cells remains <1 mM at 0.8 mM plasma. ---"
        },
        {
          "statement": "3:** *Nephrotoxicity exhibits a Hill coefficient >1 (n=1.5\u20133) due to cooperative damage pathways (e.g., NLRP3 inflammasome activation) triggered by lysosomal Li\u207a overload.",
          "type": 2,
          "confidence": 0.75,
          "mechanism": "Intracellular [Li\u207a] >5 mM disrupts lysosomal pH, releasing cathepsins that activate NLRP3, creating a nonlinear toxicity threshold.",
          "falsifiable_by": "If NLRP3-knockout mice show linear nephrotoxicity (n=1) or if lysosomal pH remains stable at [Li\u207a] <5 mM. ---"
        },
        {
          "statement": "4:** *The therapeutic index (TI) of lithium is artifactually low (~2\u20133) because brain [Li\u207a] remains below nephrotoxic thresholds (1\u20132 mM) at therapeutic doses, while kidney [Li\u207a] reaches 4\u201316 mM.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Brain [Li\u207a] saturates at ~1.5\u00d7 plasma (0.9\u20131.8 mM at 0.6\u20131.2 mM plasma), below IMPase Ki, while kidney [Li\u207a] accumulates to 5\u201320\u00d7 plasma, exceeding toxicity thresholds.",
          "falsifiable_by": "If brain [Li\u207a] at therapeutic doses exceeds 2 mM or if kidney [Li\u207a] remains <2 mM at 0.8 mM plasma. ---"
        },
        {
          "statement": "5:** *ENaC\u2019s Li\u207a permeability is the primary determinant of nephrotoxicity, not systemic [Li\u207a].",
          "type": 2,
          "confidence": 0.8,
          "mechanism": "",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 \nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\nSub-questions:  \n1. What pharmacokinetics cause differential [Li\u207a] accumulation in brain vs. kidney cells?  \n2. What low-dose targets (e.g., GSK-3\u03b2) mediate neuroprotection, and their EC50 relative to brain [Li\u207a]?  \n3. What high-dose renal targets/pathways (e.g., AQP2, ENaC) drive nephrotoxicity, and their IC50 relative to kidney [Li\u207a]?  \n4. How do these yield TI >10 despite narrow plasma window?  \n\nKey variables: plasma [Li\u207a] (low: 0.1-0.3 mM neuroprotective; therapeutic: 0.6-1.2 mM nephrotoxic), brain [Li\u207a]_intra (~1-1.5\u00d7 plasma), kidney [Li\u207a]_intra (2-20\u00d7 plasma), GSK-3\u03b2 EC50_brain (0.2-0.5 mM indirect), renal IC50 (e.g., IMPase Ki~0.5 mM, but exceeded by trapping). Relationship: tissue-specific PK amplifies renal [Li\u207a] > brain, crossing toxicity thresholds while brain stays sub-toxic.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: Low-dose neuroprotection primarily via indirect GSK-3\u03b2 inhibition (Akt-Ser9 phosphorylation), EC50_brain ~0.2-0.5 mM intracellular, achieved at plasma 0.1-0.3 mM (brain [Li\u207a] ~0.2-0.5 mM).  \nTYPE: 1  \nCONFIDENCE: 0.90  \nMECHANISM: Lithium disrupts PP2A/Akt signaling at low [Li\u207a], enhancing Ser9 phosphorylation without direct Mg\u00b2\u207a competition (Ki~2 mM).  \nFALSIFIABLE BY: Brain slice IC50 >1 mM for tau phosphorylation inhibition in Akt-knockout models.  \n\nCLAIM: Therapeutic nephrotoxicity from ENaC-mediated Li\u207a entry in collecting duct cells, yielding intracellular [Li\u207a] 3-10\u00d7 plasma (2-8 mM at 0.8 mM plasma), exceeding AQP2/vasopressin IC50 ~1-2 mM.  \nTYPE: 1  \nCONFIDENCE: 0.88  \nMECHANISM: ENaC P_Li \u2265 P_Na but Na/K-ATPase efflux k_Li << k_Na, trapping Li\u207a and downregulating AQP2 trafficking.  \nFALSIFIABLE BY: ENaC-knockout mice showing no Li\u207a accumulation or NDI at 1 mM plasma.  \n\nCLAIM: Brain [Li\u207a]_intra equilibrates to 1-1.5\u00d7 plasma (slow BBB uptake), keeping peak ~1 mM at therapeutic doses below general cytotoxicity IC50 (>5 mM).  \nTYPE: 1  \nCONFIDENCE: 0.85  \nMECHANISM: BBB restricts but equilibrates via transporters; no trapping unlike ENaC.  \nFALSIFIABLE BY: ICP-MS showing brain [Li\u207a] >2\u00d7 plasma in vivo at steady-state.  \n\nCLAIM: Dose-discrepancy from PK-driven TI expansion: effective brain TI_GSK3 ~20-50 (ED50_plasma 0.2 mM / TD50_plasma 10 mM), renal TI_ENaC ~2-3 due to 5\u00d7 accumulation factor.  \nTYPE: 2  \nCONFIDENCE: 0.82  \nMECHANISM: Accumulation factor (AF_kidney/AF_brain ~5) \u00d7 target Ki ratio shrinks apparent plasma TI below prior minimum=10.  \nFALSIFIABLE BY: Hill n=1 uniform toxicity curve across tissues, ignoring PK.  \n\nCLAIM: Renal toxicity Hill n~1.5-2 due to cooperative Li\u207a overload (lysosomal/NLRP3 threshold).  \nTYPE: 3  \nCONFIDENCE: 0.75  \nMECHANISM: Accumulation triggers supralinear inflammasome activation above ~3 mM intracellular.  \nFALSIFIABLE BY: Linear dose-response for NDI in principal cell cultures.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\nPrecise human in vivo intracellular [Li\u207a] (brain cortex, renal collecting duct) via \u2077Li-MRI/NMR at low (0.2 mM) vs. therapeutic (1 mM) plasma.  \nQuantitative AF_kidney (2-5\u00d7 or 5-20\u00d7?) from singulars; needs rat/human biopsy ICP-MS.  \nGSK-3\u03b2 indirect EC50 in human neurons (0.2-0.5 mM?).  \n Renal IC50 for AQP2 downregulation.  \nPK models integrating ENaC flux rates (P_Li/P_Na, k_efflux).\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nMeasure intracellular [Li\u207a] accumulation (ENaC-GFP cells vs. neurons) at 0.2/1 mM extracellular via \u2077Li-NMR.",
      "claims": [
        {
          "statement": "Low-dose neuroprotection primarily via indirect GSK-3\u03b2 inhibition (Akt-Ser9 phosphorylation), EC50_brain ~0.2-0.5 mM intracellular, achieved at plasma 0.1-0.3 mM (brain [Li\u207a] ~0.2-0.5 mM).",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "Lithium disrupts PP2A/Akt signaling at low [Li\u207a], enhancing Ser9 phosphorylation without direct Mg\u00b2\u207a competition (Ki~2 mM).",
          "falsifiable_by": "Brain slice IC50 >1 mM for tau phosphorylation inhibition in Akt-knockout models."
        },
        {
          "statement": "Therapeutic nephrotoxicity from ENaC-mediated Li\u207a entry in collecting duct cells, yielding intracellular [Li\u207a] 3-10\u00d7 plasma (2-8 mM at 0.8 mM plasma), exceeding AQP2/vasopressin IC50 ~1-2 mM.",
          "type": 1,
          "confidence": 0.88,
          "mechanism": "ENaC P_Li \u2265 P_Na but Na/K-ATPase efflux k_Li << k_Na, trapping Li\u207a and downregulating AQP2 trafficking.",
          "falsifiable_by": "ENaC-knockout mice showing no Li\u207a accumulation or NDI at 1 mM plasma."
        },
        {
          "statement": "Brain [Li\u207a]_intra equilibrates to 1-1.5\u00d7 plasma (slow BBB uptake), keeping peak ~1 mM at therapeutic doses below general cytotoxicity IC50 (>5 mM).",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "BBB restricts but equilibrates via transporters; no trapping unlike ENaC.",
          "falsifiable_by": "ICP-MS showing brain [Li\u207a] >2\u00d7 plasma in vivo at steady-state."
        },
        {
          "statement": "Dose-discrepancy from PK-driven TI expansion: effective brain TI_GSK3 ~20-50 (ED50_plasma 0.2 mM / TD50_plasma 10 mM), renal TI_ENaC ~2-3 due to 5\u00d7 accumulation factor.",
          "type": 2,
          "confidence": 0.82,
          "mechanism": "Accumulation factor (AF_kidney/AF_brain ~5) \u00d7 target Ki ratio shrinks apparent plasma TI below prior minimum=10.",
          "falsifiable_by": "Hill n=1 uniform toxicity curve across tissues, ignoring PK."
        },
        {
          "statement": "Renal toxicity Hill n~1.5-2 due to cooperative Li\u207a overload (lysosomal/NLRP3 threshold).",
          "type": 3,
          "confidence": 0.75,
          "mechanism": "Accumulation triggers supralinear inflammasome activation above ~3 mM intracellular.",
          "falsifiable_by": "Linear dose-response for NDI in principal cell cultures. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Neuroprotection at low doses is primarily mediated by GSK-3\u03b2 inhibition, which is effective at sub-therapeutic plasma concentrations because indirect inhibition (via Akt-mediated Ser9 phosphorylation) has an effective EC50 of ~0.2\u20130.5 mM.\n    MECHANISM: Lithium inhibits GSK-3\u03b2 both by direct competition with Mg\u00b2\u207a (Ki ~2 mM) and indirectly by disrupting Akt/PP1 regulatory circuits, with the indirect pathway dominating at low concentrations.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.85\n\n  [REPLICATED] Nephrotoxicity arises because renal collecting duct cells accumulate intracellular [Li\u207a] to 2\u20135\u00d7 plasma levels via ENaC entry with inadequate Na\u207a/K\u207a-ATPase-mediated efflux (Li\u207a is a poor substrate), meaning 0.8 mM plasma yields ~2\u20134 mM intracellular renal [Li\u207a].\n    MECHANISM: ENaC admits Li\u207a with equal or greater permeability than Na\u207a, but basolateral pumps extrude Li\u207a poorly, creating concentration trapping that exceeds IMPase Ki and disrupts vasopressin-AQP2 signaling.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.85\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] Kidney principal cells accumulate intracellular [Li] to 5-20x serum levels (e.g., 4-16 mM at 0.8 mM serum) via ENaC uptake and deficient Na+/Li+ exchange efflux.\n    SOURCE: grok | CONFIDENCE: 0.92\n  [SINGULAR] Neuroprotection arises from GSK-3\u03b2 inhibition at low [Li] (EC50_brain ~0.3 mM intracellular, Hill n=1), suppressing tau hyperphosphorylation and apoptosis.\n    SOURCE: grok | CONFIDENCE: 0.91\n  [SINGULAR] The dose-discrepancy is a direct consequence of differential bioaccumulation combined with differential target affinity.\n    SOURCE: gemini | CONFIDENCE: 0.9\n  [SINGULAR] Brain [Li] equilibrates to ~0.8-1.5x serum with slower uptake, reaching 0.1-1.5 mM at low doses sufficient for GSK-3\u03b2 inhibition (IC50 0.4-2 mM).\n    SOURCE: grok | CONFIDENCE: 0.88\n  [SINGULAR] Nephrotoxicity shows Hill n>1 (1.5-3) due to threshold accumulation triggering cooperative events like lysosomal Li+ overload and NLRP3 inflammasome.\n    SOURCE: grok | CONFIDENCE: 0.82\n  [SINGULAR] The therapeutic index (TI) of lithium is artifactually low (~2\u20133) due to tissue-specific accumulation, not intrinsic toxicity; brain [Li] remains below nephrotoxic thresholds at therapeutic doses.\n    SOURCE: mistral | CONFIDENCE: 0.8\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 37% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1.  **Differential Pharmacokinetics:** What is the quantitative relationship between serum [Li\u207a] and steady-state intracellular [Li\u207a] in target neurons versus renal collecting duct principal cells?\n2.  **Differential Pharmacodynamics:** What are the effective intracellular [Li\u207a] dose-response curves for the primary neuroprotective target (GSK-3\u03b2 signaling) and the primary nephrotoxic targets (e.g., IMPase, GSK-3\u03b2, downstream effectors)?\n3.  **Mechanism Integration:** How does the intersection of these differential PK/PD profiles explain the narrow therapeutic window, and does nephrotoxicity exhibit non-linear, threshold-based behavior?\n\nKey variables: [Li\u207a]serum, [Li\u207a]neuron_intra, [Li\u207a]kidney_intra, EC50_GSK3\u03b2(indirect), IC50_IMPase, Hill_coefficient_nephrotoxicity. The core relationship is that [Li\u207a]kidney_intra >> [Li\u207a]neuron_intra at a given [Li\u207a]serum.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\n\nCLAIM: The functional therapeutic window is created by differential bioaccumulation: brain intracellular [Li\u207a] equilibrates near serum levels (~1x), while renal collecting duct cells concentrate Li\u207a to >5x serum levels via apical ENaC influx and poor basolateral efflux.\nTYPE: 1\nCONFIDENCE: 0.95\nMECHANISM: Neurons maintain ionic homeostasis via efficient transporters, whereas renal principal cells are specialized for Na\u207a reabsorption, a system Li\u207a hijacks for entry but not for efficient exit, leading to concentration trapping.\nFALSIFIABLE BY: In vivo imaging (e.g., \u2077Li-MRI) demonstrating that intracellular [Li\u207a] in the renal medulla does not exceed 2x the concentration in the prefrontal cortex at therapeutic serum levels.\n\nCLAIM: Neuroprotection and nephrotoxicity are governed by distinct molecular pathways with different concentration thresholds; the former is a high-sensitivity pathway (indirect GSK-3\u03b2 inhibition, EC50 ~0.3 mM), while the latter requires higher concentrations (>2 mM) to inhibit multiple targets like IMPase and directly inhibit GSK-3\u03b2.\nTYPE: 1\nCONFIDENCE: 0.90\nMECHANISM: Low intracellular [Li\u207a] in neurons is sufficient to modulate the highly sensitive Akt/PI3K phosphorylation of GSK-3\u03b2, whereas the high [Li\u207a] in kidney cells is required to competitively inhibit multiple Mg\u00b2\u207a-dependent enzymes.\nFALSIFIABLE BY: Evidence that a highly specific, non-lithium GSK-3\u03b2 inhibitor causes nephrotoxicity at doses equivalent to its neuroprotective effect.\n\nCLAIM: Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li\u207a accumulation past a critical threshold (~2-3 mM) triggers cooperative, catastrophic events like NLRP3 inflammasome activation.\nTYPE: 2\nCONFIDENCE: 0.80\nMECHANISM: Beyond simple enzyme inhibition, supraphysiological intracellular cation levels trigger stress responses that function as all-or-none switches, amplifying cellular damage in a highly cooperative manner.\nFALSIFIABLE BY: In vitro dose-response studies in human renal principal cells showing lithium-induced cytotoxicity follows a simple monophasic curve with a Hill coefficient of ~1.0.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n1.  The precise, time-resolved in vivo intracellular concentrations of Li\u207a in human neurons vs. renal principal cells at steady-state. Current estimates are derived primarily from animal models or post-mortem tissue.\n2.  The identity and relative contribution of basolateral Li\u207a efflux transporters in renal cells. Understanding these could provide a target for mitigating accumulation.\n3.  The exact intracellular [Li\u207a] threshold that triggers cooperative toxicity events (e.g., inflammasome activation) and whether this threshold varies significantly between individuals due to genetic polymorphisms in ion channels or stress-response pathways.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nPerform simultaneous \u2077Li-MRI on the brain and kidneys of healthy human volunteers across a dose-escalation protocol to directly quantify the tissue-specific accumulation ratios and validate the core PK model.",
      "claims": [
        {
          "statement": "The functional therapeutic window is created by differential bioaccumulation: brain intracellular [Li\u207a] equilibrates near serum levels (~1x), while renal collecting duct cells concentrate Li\u207a to >5x serum levels via apical ENaC influx and poor basolateral efflux.",
          "type": 1,
          "confidence": 0.95,
          "mechanism": "Neurons maintain ionic homeostasis via efficient transporters, whereas renal principal cells are specialized for Na\u207a reabsorption, a system Li\u207a hijacks for entry but not for efficient exit, leading to concentration trapping.",
          "falsifiable_by": "In vivo imaging (e.g., \u2077Li-MRI) demonstrating that intracellular [Li\u207a] in the renal medulla does not exceed 2x the concentration in the prefrontal cortex at therapeutic serum levels."
        },
        {
          "statement": "Neuroprotection and nephrotoxicity are governed by distinct molecular pathways with different concentration thresholds; the former is a high-sensitivity pathway (indirect GSK-3\u03b2 inhibition, EC50 ~0.3 mM), while the latter requires higher concentrations (>2 mM) to inhibit multiple targets like IMPase and directly inhibit GSK-3\u03b2.",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "Low intracellular [Li\u207a] in neurons is sufficient to modulate the highly sensitive Akt/PI3K phosphorylation of GSK-3\u03b2, whereas the high [Li\u207a] in kidney cells is required to competitively inhibit multiple Mg\u00b2\u207a-dependent enzymes.",
          "falsifiable_by": "Evidence that a highly specific, non-lithium GSK-3\u03b2 inhibitor causes nephrotoxicity at doses equivalent to its neuroprotective effect."
        },
        {
          "statement": "Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li\u207a accumulation past a critical threshold (~2-3 mM) triggers cooperative, catastrophic events like NLRP3 inflammasome activation.",
          "type": 2,
          "confidence": 0.8,
          "mechanism": "Beyond simple enzyme inhibition, supraphysiological intracellular cation levels trigger stress responses that function as all-or-none switches, amplifying cellular damage in a highly cooperative manner.",
          "falsifiable_by": "In vitro dose-response studies in human renal principal cells showing lithium-induced cytotoxicity follows a simple monophasic curve with a Hill coefficient of ~1.0. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Neuroprotection at low doses is primarily mediated by GSK-3\u03b2 inhibition, which is effective at sub-therapeutic plasma concentrations because indirect inhibition (via Akt-mediated Ser9 phosphorylation) has an effective EC50 of ~0.2\u20130.5 mM.\n    MECHANISM: Lithium inhibits GSK-3\u03b2 both by direct competition with Mg\u00b2\u207a (Ki ~2 mM) and indirectly by disrupting Akt/PP1 regulatory circuits, with the indirect pathway dominating at low concentrations.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.85\n\n  [REPLICATED] Nephrotoxicity arises because renal collecting duct cells accumulate intracellular [Li\u207a] to 2\u20135\u00d7 plasma levels via ENaC entry with inadequate Na\u207a/K\u207a-ATPase-mediated efflux (Li\u207a is a poor substrate), meaning 0.8 mM plasma yields ~2\u20134 mM intracellular renal [Li\u207a].\n    MECHANISM: ENaC admits Li\u207a with equal or greater permeability than Na\u207a, but basolateral pumps extrude Li\u207a poorly, creating concentration trapping that exceeds IMPase Ki and disrupts vasopressin-AQP2 signaling.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.85\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] Kidney principal cells accumulate intracellular [Li] to 5-20x serum levels (e.g., 4-16 mM at 0.8 mM serum) via ENaC uptake and deficient Na+/Li+ exchange efflux.\n    SOURCE: grok | CONFIDENCE: 0.92\n  [SINGULAR] Neuroprotection arises from GSK-3\u03b2 inhibition at low [Li] (EC50_brain ~0.3 mM intracellular, Hill n=1), suppressing tau hyperphosphorylation and apoptosis.\n    SOURCE: grok | CONFIDENCE: 0.91\n  [SINGULAR] The dose-discrepancy is a direct consequence of differential bioaccumulation combined with differential target affinity.\n    SOURCE: gemini | CONFIDENCE: 0.9\n  [SINGULAR] Brain [Li] equilibrates to ~0.8-1.5x serum with slower uptake, reaching 0.1-1.5 mM at low doses sufficient for GSK-3\u03b2 inhibition (IC50 0.4-2 mM).\n    SOURCE: grok | CONFIDENCE: 0.88\n  [SINGULAR] Nephrotoxicity shows Hill n>1 (1.5-3) due to threshold accumulation triggering cooperative events like lysosomal Li+ overload and NLRP3 inflammasome.\n    SOURCE: grok | CONFIDENCE: 0.82\n  [SINGULAR] The therapeutic index (TI) of lithium is artifactually low (~2\u20133) due to tissue-specific accumulation, not intrinsic toxicity; brain [Li] remains below nephrotoxic thresholds at therapeutic doses.\n    SOURCE: mistral | CONFIDENCE: 0.8\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 37% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1. **Tissue-Specific Pharmacokinetics:** What are the quantitative relationships between plasma [Li\u207a], brain intracellular [Li\u207a], and kidney collecting duct intracellular [Li\u207a] at steady-state for low (0.2-0.5 mM) vs. therapeutic (0.6-1.2 mM) plasma doses?\n2. **Target Engagement Profiles:** What are the effective intracellular concentrations (EC50/Ki) and Hill coefficients for Li\u207a at its key neuroprotective (e.g., GSK-3\u03b2 inhibition via indirect pathway) vs. nephrotoxic (e.g., IMPase inhibition, disruption of vasopressin signaling) targets?\n3. **Mechanistic Link to Phenotype:** How do the concentration-response relationships from Q1 & Q2 map onto the observed neuroprotective (sub-therapeutic plasma) and nephrotoxic (therapeutic plasma) dose ranges? Is the discrepancy explained purely by tissue accumulation, target sensitivity, or both?\n\nKey Variables: Plasma [Li\u207a] (input), Brain:[Plasma] ratio, Kidney:[Plasma] ratio, EC50_GSK3\u03b2 (indirect), Ki_IMPase, Hill coefficients for each effect.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: The primary mechanism for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding the Ki for IMPase inhibition (~0.8 mM), while brain neurons achieve only 0.8-1.2x plasma [Li\u207a",
      "claims": [
        {
          "statement": "The primary mechanism for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding the Ki for IMPase inhibition (~0.8 mM), while brain neurons achieve only 0.8-1.2x plasma [Li\u207a",
          "type": 2,
          "confidence": 0.5,
          "mechanism": "for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding the Ki for IMPase inhibition (~0.8 mM), while brain neurons achieve only 0.8-1.2x plasma [Li\u207a",
          "falsifiable_by": ""
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.14712661123369197,
    "cosine": 0.7617817640304565,
    "jsd": 0.1522721453854873,
    "kappa": 0.8794575822722012,
    "type_distribution": {
      "0": 0.0,
      "1": 0.5555555555555556,
      "2": 0.3888888888888889,
      "3": 0.05555555555555555
    },
    "type_01_ratio": 0.5555555555555556,
    "n_claims_per_model": [
      4,
      5,
      5,
      3,
      1
    ]
  },
  "total_calls": 5
}